The initiative aligns with global psycho-oncology standards that advocate routine distress screening as a core quality benchmark in cancer treatment
The acquisition complements Gilead’s existing oncology expertise and development infrastructure
The results were consistent across both the 10 mg and 40 mg treatment arms
TriNetX will provide Regeneron secure, licensed access to de-identified health data from its global network of health system partners
Opioid dependence remains a major driver of death and disease worldwide
Biopharma companies face persistent hurdles in cell line development, including long timelines, low yields, and high failure rates for novel molecules
The new capital is expected to fund the company through 2029
Interchangeable biosimilars to Prolia and Xgeva target osteoporosis and cancer-related bone complications in a $5 billion U.S. market
The acquisition aims to bolster Merck’s hematology portfolio with Terns’ lead oncology candidate, TERN-701
Subscribe To Our Newsletter & Stay Updated
